Literature DB >> 9695201

The use of unproven methods of treatment by cancer patients. Frequency, expectations and cost.

M Miller1, M J Boyer, P N Butow, M Gattellari, S M Dunn, A Childs.   

Abstract

The use of unproven therapies is of concern for a number of reasons, including the lack of scientific evidence of support them, their potential financial costs and the possibility of interference with conventional treatment. This study explored the prevalence, predictors and experiences of unproven therapy use by cancer patients attending an oncology clinic at an Australian teaching hospital. A questionnaire was administered to patients whilst they were waiting for a consultation with their oncologist. A total of 173 patients were invited to participate, and 156 consented to complete the survey (90%). Over half the patients (81, 52%) had used at least one unproven therapy since their diagnosis, and 28% had used three or more. Patients most commonly practised mediation/relaxation, changed their diet and used multi-vitamins. Most expected that the therapies would aid their conventional treatments and make them feel more in control of their situation. Benefits reported were largely psychological, such as an increased sense of control or a reduction in anxiety. Younger patients, those with early stage or advanced metastatic disease and those who had used unproven therapies prior to developing cancer were more likely to use unproven therapies. Health professionals involved in the care of cancer patients should be prepared to discuss the use of unproven therapies and try to identify and deal with unmet needs to help patients to cope with their illness.

Entities:  

Mesh:

Year:  1998        PMID: 9695201     DOI: 10.1007/s005200050175

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  19 in total

1.  Dangerous nutrition? Calcium, vitamin D, and shark cartilage nutritional supplements and cancer-related hypercalcemia.

Authors:  Ruth Lagman; Declan Walsh
Journal:  Support Care Cancer       Date:  2003-01-15       Impact factor: 3.603

2.  Is a biopsychosocial-spiritual approach relevant to cancer treatment? A study of patients and oncology staff members on issues of complementary medicine and spirituality.

Authors:  Eran Ben-Arye; Gil Bar-Sela; Moshe Frenkel; Abraham Kuten; Doron Hermoni
Journal:  Support Care Cancer       Date:  2005-08-16       Impact factor: 3.603

3.  [Influence of ML-1 standardized mistletoe extract on the quality of life in head and neck cancer patients].

Authors:  M K Steuer-Vogt; V Bonkowsky; M Scholz; C Fauser; K Licht; P Ambrosch
Journal:  HNO       Date:  2006-04       Impact factor: 1.284

Review 4.  Cancer patient disclosure and patient-doctor communication of complementary and alternative medicine use: a systematic review.

Authors:  Esther L Davis; Byeongsang Oh; Phyllis N Butow; Barbara A Mullan; Stephen Clarke
Journal:  Oncologist       Date:  2012-08-29

5.  Integrative oncology in Australia.

Authors:  Daniel Weber; Janelle M Wheat; Geoffrey M Currie
Journal:  Chin J Integr Med       Date:  2011-04-21       Impact factor: 1.978

6.  Impact of medical Qigong on quality of life, fatigue, mood and inflammation in cancer patients: a randomized controlled trial.

Authors:  B Oh; P Butow; B Mullan; S Clarke; P Beale; N Pavlakis; E Kothe; L Lam; D Rosenthal
Journal:  Ann Oncol       Date:  2009-10-30       Impact factor: 32.976

7.  Trick or treat? Australian newspaper portrayal of complementary and alternative medicine for the treatment of cancer.

Authors:  Reegan Mercurio; Jaklin Ardath Eliott
Journal:  Support Care Cancer       Date:  2009-11-27       Impact factor: 3.603

8.  Use of complementary and alternative therapies: a national multicentre study of oncology health professionals in Norway.

Authors:  A Kolstad; T Risberg; Y Bremnes; T Wilsgaard; H Holte; O Klepp; O Mella; E Wist
Journal:  Support Care Cancer       Date:  2004-02-06       Impact factor: 3.603

Review 9.  Use of complementary and alternative medical therapy by patients with primary brain tumors.

Authors:  Terri S Armstrong; Mark R Gilbert
Journal:  Curr Neurol Neurosci Rep       Date:  2008-05       Impact factor: 5.081

10.  Attitudes to terminal patients' unorthodox therapy: Finnish doctors' responses to a case scenario.

Authors:  Heikki Hinkka; Elise Kosunen; Ulla-Kaija Lammi; Riina Metsänoja; Pirkko Kellokumpu-Lehtinen
Journal:  Support Care Cancer       Date:  2003-11-20       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.